| 1 |
34820552 | Resetting amino acid metabolism of cancer cells by ATB0,+-targeted nanoparticles for enhanced anticancer therapy. | 2022 Mar |
2 |
| 2 |
34939319 | Design, synthesis, and molecular modeling of quinoline-based derivatives as anti-breast cancer agents targeting EGFR/AKT signaling pathway. | 2022 Mar |
1 |
| 3 |
34958115 | Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells. | 2022 Feb |
1 |
| 4 |
35270029 | Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis. | 2022 Mar 7 |
1 |
| 5 |
35276440 | Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. | 2022 Apr |
1 |
| 6 |
35549881 | Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini Review. | 2022 May 12 |
1 |
| 7 |
35572995 | Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection? | 2022 |
1 |
| 8 |
35617997 | Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib. | 2022 Jul |
2 |
| 9 |
33085768 | A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. | 2021 Mar 25 |
2 |
| 10 |
33122343 | Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. | 2021 Feb 1 |
2 |
| 11 |
33150390 | EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. | 2021 Jan 23 |
1 |
| 12 |
33222246 | Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. | 2021 Jun |
1 |
| 13 |
33398673 | Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation. | 2021 Apr |
1 |
| 14 |
33735711 | Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. | 2021 May |
1 |
| 15 |
33771774 | Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain. | 2021 Mar 26 |
1 |
| 16 |
33801244 | Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells. | 2021 Mar 2 |
2 |
| 17 |
33857297 | Discovering novel cancer bio-markers in acquired lapatinib resistance using Bayesian methods. | 2021 Sep 2 |
1 |
| 18 |
33928964 | Binding of tyrosine kinase inhibitor to epidermal growth factor receptor: surface-enhanced infrared absorption microscopy reveals subtle protein secondary structure variations. | 2021 Apr 30 |
2 |
| 19 |
34074257 | Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. | 2021 Jun 1 |
1 |
| 20 |
34093999 | Substantial cell apoptosis provoked by naked PAMAM dendrimers in HER2-positive human breast cancer via JNK and ERK1/ERK2 signalling pathways. | 2021 |
1 |
| 21 |
34159337 | Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen. | 2021 Jun 15 |
2 |
| 22 |
34290605 | Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells. | 2021 |
1 |
| 23 |
34382727 | miR-221 confers lapatinib resistance by negatively regulating p27kip1 in HER2-positive breast cancer. | 2021 Oct |
1 |
| 24 |
34399705 | A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer. | 2021 Aug 16 |
1 |
| 25 |
34451888 | Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2. | 2021 Aug 12 |
1 |
| 26 |
34482024 | Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs. | 2021 Oct 22 |
1 |
| 27 |
34535639 | Post-transcriptional screen of cancer amplified genes identifies ERBB2/Her2 signaling as AU-rich mRNA stability-promoting pathway. | 2021 Sep 17 |
1 |
| 28 |
34830108 | Effect of EGFR on SQSTM1 Expression in Malignancy and Tumor Progression of Oral Squamous Cell Carcinoma. | 2021 Nov 12 |
1 |
| 29 |
31177402 | The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. | 2020 Jun |
1 |
| 30 |
32320483 | Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes. | 2020 Oct |
1 |
| 31 |
32378049 | Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells. | 2020 Oct |
2 |
| 32 |
32547705 | Efficacy of osimertinib against EGFRvIII+ glioblastoma. | 2020 Jun 2 |
2 |
| 33 |
32800546 | Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway. | 2020 Oct 20 |
1 |
| 34 |
32919134 | Targeting EGFR tyrosine kinase: Synthesis, in vitro antitumor evaluation, and molecular modeling studies of benzothiazole-based derivatives. | 2020 Nov |
1 |
| 35 |
32956836 | The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. | 2020 Nov |
1 |
| 36 |
33013420 | Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer. | 2020 |
2 |
| 37 |
33087324 | Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. | 2020 Dec 15 |
2 |
| 38 |
33183223 | Quantitative Structure-Mutation-Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction. | 2020 Nov 12 |
1 |
| 39 |
33194604 | Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review. | 2020 |
1 |
| 40 |
33371069 | Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report. | 2020 Dec 18 |
4 |
| 41 |
30242055 | Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells. | 2019 Feb |
1 |
| 42 |
30273693 | PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner. | 2019 Oct |
1 |
| 43 |
30343043 | Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study. | 2019 Feb |
2 |
| 44 |
30590459 | Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors. | 2019 Aug 22 |
5 |
| 45 |
30657766 | Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. | 2019 |
2 |
| 46 |
30665034 | Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers. | 2019 Apr |
1 |
| 47 |
30738402 | Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. | 2019 Feb 8 |
1 |
| 48 |
30781364 | (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo. | 2019 Feb 15 |
3 |
| 49 |
30842786 | LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib. | 2019 |
4 |
| 50 |
31024833 | Lapatinib-Loaded Nanocapsules Enhances Antitumoral Effect in Human Bladder Cancer Cell. | 2019 |
1 |